Mifepristone Survives Another Supreme Court Scare — for Now

The Supreme Court’s decision to block a lower court order targeting mifepristone has sparked relief among reproductive rights advocates, but what does this ruling really mean? On the surface, it appears that abortion advocates have scored a temporary victory. However, beneath the surface lies a complex landscape.

One of the most striking aspects of this case is the judicial activism on display in Danco Laboratories v. Louisiana. The Fifth Circuit’s order was not just an attempt to ban mifepristone outright but an exercise in creative reinterpretation of federal law. By targeting mail-order distribution, the court effectively sought to create a patchwork of regulations that would render the FDA’s existing guidelines toothless.

The Supreme Court has a long history of handling abortion-related cases through its shadow docket, which refers to emergency motions and other expedited matters that bypass traditional judicial review. In recent years, there has been a disturbing trend of the Court using this mechanism to quietly undermine reproductive rights.

In Danco Laboratories v. Louisiana, at least five justices felt compelled to intervene, blocking the Fifth Circuit’s order and preserving mifepristone’s availability for now. The fact that Justices Clarence Thomas and Samuel Alito penned dissenting opinions suggests deep divisions within the Court on these issues.

Thomas’s characterization of pharmaceutical companies as a “criminal enterprise” is particularly egregious. His reliance on the Comstock Act, a 19th-century law largely superseded by modern legislation, reveals a misunderstanding of the complexities surrounding mifepristone’s regulation.

Alito’s dissent is more nuanced but no less problematic. His suggestion that one of the drug companies involved in mifepristone’s production is engaged in an “unlawful conspiracy” smacks of McCarthyism. By implying that a company’s product is illicit merely because it’s banned in certain states, Alito exposes his own biases and misunderstandings.

For now, mifepristone remains accessible to patients across the country. However, this reprieve raises questions about its long-term implications. Will it embolden advocates to continue fighting for reproductive rights, or will it lull them into a false sense of security? The fact that Congress and the FDA have not yet attempted to restrict mifepristone’s availability is hardly reassuring.

As we move forward, it’s essential to recognize that this ruling is just one battle in a long war. Abortion advocates must remain vigilant, pushing back against judicial activism and legislative attempts to curtail reproductive rights. In the face of an increasingly hostile Supreme Court, evidence-based policy making and resisting the politicization of medicine are crucial.

The coming months will be crucial as Congress and state legislatures weigh in on the issue. Ultimately, mifepristone’s fate will be decided in a future ruling. Will the Court uphold its existing precedent, or will it succumb to pressure from anti-abortion groups? One thing is clear: reproductive rights advocates must remain steadfast in their commitment to protecting access to essential healthcare services like mifepristone.